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Methicillin-resistant Staphylococcus aureus (MRSA) has become a worrisome
superbug. This work aimed at studying the effects of two class IIb bacteriocins,
enterocins DD28 and DD93 as anti-MRSA agents. Thus, these bacteriocins were
purified, from the cultures supernatants of Enterococcus faecalis 28 and 93, using a
simplified purification procedure consisting in a cation exchange chromatography and
a reversed-phase high-performance liquid chromatography. The anti-Staphylococcal
activity was shown in vitro by the assessment of the minimal inhibitory concentration
(MIC), followed by a checkerboard and time-kill kinetics experiments. The data unveiled
a clear synergistic effect of enterocins DD28 and DD93 in combination with erythromycin
or kanamycin against the clinical MRSA-S1 strain. Besides, these combinations
impeded as well the MRSA-S1 clinical strain to setup biofilms on stainless steel and
glace devices.
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INTRODUCTION
Staphylococcus aureus is among the five top pathogens found as normal resident of the skin
and nasal flora in at least 25–30% of healthy humans, and it is associated with hospital
acquired (HA-MRSA) and community acquired (CA-MRSA) infections ranging from superficial
wound infections to life-threatening deep infections such as septicemia, endocarditis, and toxic
shock syndrome (David and Daum, 2010). Antibiotic resistance and biofilm-forming capabilities
contribute to the success of S. aureus as a harsh human pathogen in the healthcare as well as in the
community settings. The last decade has seen a welcome increase in the number of agents available
for the treatment of MRSA including antibiotics such as fluoroquinolones, linezolid, rifampin,
and antimicrobial peptides (AMPs) such as daptomycin, tigecycline, and mainly vancomycin.
Resistance to methicillin was observed in 1961, 1 year after the commercial availability of this
antibiotic. Susceptibility to vancomycin was first reported in 1996 in Japan, leading to emergence
of heterogeneous resistance to vancomycin phenotype (Spagnolo et al., 2014). MRSA with
reduced susceptibility to vancomycin was reported in ocular infections, and there was a rise in
S. aureus resistance to new and old generation fluoroquinolones that were commonly used for
prophylaxis after intravitreal injections and intraocular surgeries (Sadaka et al., 2015). Daptomycin
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which is considered drug of last resort after vancomycin
breakdown for the treatment of MRSA infections (Claeys et al.,
2015) has shown non-inferiority to vancomycin in the treatment
of MRSA bacteremia (Holmes et al., 2015) was threatened
because of the emergence of daptomycin resistance, especially
in the deep-seated infections (Claeys et al., 2015). MRSA are
responsible of diverse infections, especially in the healthcare
structures. The increasing resistance of Gram-positive bacteria
to the broad-spectrum antibiotics and the lack of new molecules
expected to become available in the near future, advocates
the need of novel anti-MRSA agents and therapeutic options
(Tängdén, 2014).
Antimicrobial peptides were largely admitted as potential
alternatives to traditional antibiotics in order to combat the
scaring and increasing bacterial infections. AMPs are produced
by all the living cells but also gathered by chemical synthesis
and controlled enzymatic digestion of proteins. Bacteria are
known as great sources of AMPs such as lipopeptides and
bacteriocins. Conversely to lipopeptides, the bacteriocins are
AMPs of proteinaceous nature, ribosomally synthesized mainly
by lactic acid bacteria (LAB) (Drider and Rebuffat, 2011). LAB
of Enterococcus genus produce a great number of bacteriocins
designed as enterocins. Enterocins-producing strains were
isolated from a wide range of sources, including fermented food,
environmental, and clinical (Ishibashi et al., 2012). Enterocins
resulted to be mainly produced by Enterococcus faecalis and
E. faecium species (Goto and Yan, 2011). Enterocins produced
by E. muntii, E. avium, E. durans, and E. hirae strains were
also reported in the literature (Saavedra et al., 2004; Batdorj
et al., 2006; Sánchez et al., 2007; Birri et al., 2010). Multiple
enterocins-producing strains were characterized for their large
range of activities, inhibiting the growth of many undesirable
bacteria (Ishibashi et al., 2012). Cintas et al. (2000) underlined
the potential of E. faecium L50 to produce three different
enterocins named enterocins L50A and L50B, enterocin P,
and enterocin Q which act synergistically and inhibit the
growth of many Gram-positive bacteria. Remarkably, enterocins
were also produced by enterococci from the gastrointestinal
tract origins of humans, animals, human infection sites and
healthy babies feces (Tomita et al., 1996; Kang and Lee, 2005;
Sawa et al., 2012) A compilation of studies underpinning the
inhibitory activities of enterocins, pointed out the capabilities
of enterocin E-760 to inhibit the growth of Salmonella enterica,
Escherichia coli, Pseudomonas aeruginosa, Campylobacter jejuni,
and Staphylococcus aureus (Line et al., 2008). These data show
that bacteriocins are sustainable antimicrobials that could be used
alone or in combination with antibiotics.
Related to that, the combinations of antibiotics were presented
as a promising option in the management of antibiotics use and
treatment of life-threatening infections (Bassetti and Righi, 2015;
Leone et al., 2015). The antibiotics were successfully combined to
chemical or physical agents (Sawa et al., 2012; Kullar et al., 2015).
In direct line, the combinations of antibiotics and bacteriocins
could offer novel therapeutic options as supported by different
and successful in vitro studies (Naghmouchi et al., 2010, 2011,
2012, 2013; Hassan et al., 2012; Mataraci and Dosler, 2012;
Wolska et al., 2012; Singh et al., 2014).
In this study, enterocins DD28 and DD93 produced by
E. faecalis 28 and E. faecalis 93 were purified and their
DNA sequences were determined. The anti-MRSA activity was
determined against the MRSA-S1 clinical strain. In spite of
their relatively high MICs values against the aforementioned
target, enterocins DD28 and DD93 were able to synergize
with kanamycin or erythromycin and switch from resistance to
susceptibility the phenotype of MRSA-S1 strain. Furthermore,
these combinations hampered biofilm formation of the MRSA-S1
strain on AISI 304L stainless steel and glass devices. Overall, the
combinations of antibiotics and bacteriocins offer a novel strategy
to fight against pathogenic bacteria.
MATERIALS AND METHODS
Strains, Cultivation, and Antibacterial
Susceptibility
Enterococcus faecalis DD28 and E. faecalis DD93 recently isolated
from meconium (Al-Atya et al., 2015) were grown in MRS (de
Man, Rogosa, and Sharpe) medium (De Man et al., 1960) at 37◦C
for 16 to 18 h. S. epidermidis (Kindly provided by Dr. Anne
Vachée, Roubaix hospital, France), S. aureus ATCC 33862, and
Methicillin Resistant S. aureus (MRSA) strains including MRSA
ATCC 43300, MRSA-S1, and MRSA-2 strains (kindly provided
by Dr. Gilles Prévost, Strasbourg University, France) were grown
in Brain Heart Infusion (BHI) broth at 37◦C for appropriate
experimental time. Listeria innocua CIP80.11 was grown at 37◦C
for overnight in BHI or Muller Hinton media according to the
experiment purposes.
Antibiotic susceptibility was performed by VITEK 2 system
(Bio-Mérieux, France), encompassing nearly all important
antibiotics. Antibiotic susceptibility and MICs were determined
and analyzed according to the French Committee on
Antimicrobial Susceptibility Testing (French Committee on
Antimicrobial Susceptibility Testing [FCAST], 2015).
Purification of Bacteriocins and
Determination of Their Masses
Purification of enterocins DD28 and DD93 was performed
at room temperature using two-step methods adapted from
Abriouel et al. (2003). Briefly 1,000 ml of the cell-free culture
supernatant of E. faecalis 28 and E. faecalis 93 were adjusted to pH
6.3 using 5 M NaOH. Then Carboxymethyl Sephadex CM-25 (GE
Healthcare, Sweden) gel slurry equilibrated in distilled water was
added to culture supernatants (1:40, v/v). The obtained mixture
was held under stirring for 30 min and decanted for additional
30 min. The supernatants were removed, and the sediment gel
slurry containing the bacteriocin activity, captured by cation
interactions with the matrix was loaded onto a 10 cm × 50 cm
glass column. The gels was washed with one volume (1V) of
distilled water and 2V of 0.5 M NaCl, followed by 2V of 1.5 M
NaCl to elute the adsorbed bacteriocin. The obtained fractions
were filtrated through 0.22 µm pore size low protein binding
filters (Millex GV; Millipore Corp., Belford, MA, USA) and tested
for bacteriocin activity.
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The active fractions from the cation exchange chromato-
graphy were applied onto a reversed-phase high-performance
liquid chromatography (RP-HPLC) by using a column C-18
(5 µm, 250 mm× 3 mm, VYDAC 218 TP53; Grace, Deerfield, IL,
USA) previously equilibrated in solvent A (10 mM trifluoroacetic
acid, TFA; Fluka), at a flow rate of 5 ml/min. Non-adsorbed
material was eliminated by washing the column with solvent
A until the UV absorbance of the eﬄuent at 210 nm reached
baseline. The material retained in the column was eluted with
a gradient ranging from 0 to 40% of solvent B [isopropyl
alcohol/acetonitrile (2:1, v/v) in 40 mM TFA] in over 5 min, then
followed by increasing of solvent B gradient from 40 to 100% for
over 25 min at a flow rate of 2.5 ml/min. Fractions of the column
eﬄuent were collected according to their UV light absorbance,
lyophilized and dissolved again in distilled water before being
tested for bacteriocin activity.
Antimicrobial activity was tested along the purification
procedure on the cell-free supernatant (CFS), partly purified
peptide (upon cation exchange step) and purified peptide
(upon Reversed Phase-HPLC step). Arbitrary units (AU) were
calculated based on the spot method (Naghmouchi et al., 2011).
Thus, the resulting sample was serially diluted twofold with filter-
sterilized phosphate buffer. Ten micro liter of each diluted sample
was spotted onto the plate of BHI medium containing L. innocua
CIP80.11 as indictor strain. The plates were then incubated at
37oC overnight, and the titer was defined as the reciprocal of the
highest dilution (2n) that resulted in inhibition of the indicator
lawn. The AU of antibacterial activity per milliliter was defined as
2n × 1,000 µl/10µl. The protein concentration was determined
by BCA assay using Sigma–Aldrich BCA kit (USA).
Purified enterocins were analyzed with an Ultraflex MALDI-
ToF/ToF mass spectrometer (Bruker, Bremen, Germany)
equipped with a smart beam laser. Samples were analyzed
using an accelerating voltage of 25 kV and matrix suppression in
deflexion mode at m/z 1000. The laser power was set to just above
the threshold of ionization (around 60%). Spectra were acquired
in reflector positive mode in the range of 3 000 at 10 000 Da. Each
spectrum was the result of 1 000 laser shots per m/z segment per
sample delivered in 10 sets of 50 shots distributed in random
locations on the surface of the matrix spot. The instrument
was externally calibrated in positive reflector mode using
Bradykinin (1–7) [M+H]+ 757.3991, Angiotensin II [M+H]+
1 046.5418, Angiotensin I [M+H]+ 1 296.6848, Substance P
[M+H]+ 1347.7354, Bombesin [M+H]+ 1619.8223, ACTH
(1–17) [M+H]+ 2 093,0862. For analysis, a mixture of 1 µl of
purified enterocin and 1 µl of α-cyano-4-hydroxycinnamic acid
(10 mg/ml 70:30 water/acetonitrile with 0.1% TFA) was spotted
onto a MALDI-TOF MTP 384 target plate (Bruker Daltonik
GmbH, Leipzig, Germany) according to the procedure of the
dried-droplet preparation.
Minimal Inhibitory Concentrations (MICs)
and Checkerboard Experiments
A pure colony of each Staphylococcus strains used in this study
was grown overnight in BHI medium at 37◦C. Afterward 10 µl
of each overnight culture were added to the wells of bioassay
microplates of 96 well cell culture plate (Cellstar) containing
different concentrations of enterocins DD28 and DD93, ranging
from 50 to 800 mg/l of each bacteriocin. The minimal inhibitory
concentration (MIC) is defined as the lowest concentration of an
antibiotic that will inhibit the visible growth of a microorganism
after overnight incubation.
Antimicrobial agent interactions were determined using
checkerboard assay. The concentrations used for enterocins
DD28 and DD93 were comprised between 25 and 400 mg/l,
while those used for erythromycin and kanamycin were ranging
from 0.25 to 64 mg/l. Microplates were inoculated with MRSA-
S1 strain at about 106 CFU/ml, in a final volume of 200 µl per
well, and incubated overnight at 37◦C. The fractional inhibitory
concentration index (FICI) was calculated for each combination
using the following formula: FICA + FICB = FICI, where
FICA = MIC of drug A in combination/MIC of drug A alone,
and FICB=MIC of drug B in combination/MIC of drug B alone.
The FICI was interpreted as follow: synergism = FICI ≤ 0.5;
indifference= 0.5< FICI≤ 4; antagonism= FICI> 4 (Petersen
et al., 2006).
Killing Curves Experiment
This experiment was realized on the MRSA strain. Tubes
containing BHI supplemented with enterocin DD28, enterocin
DD93, erythromycin, kanamycin or combination of bacteriocin
and antibiotic, at previously defined concentrations during
checkboard assay, were inoculated with MRSA-S1 strain to a
density of about 5 × 105 CFU/ml in a final volume of 5 ml
and incubated at 37◦C for 24 h. The killing kinetics of the
enterocin DD28 alone, enterocin DD93 alone, erythromycin
alone, kanamycin alone and enterocin DD28 or enterocin
DD93 in combination with erythromycin or kanamycin was
assessed against MRSA-S1 strain using standard time-killing
experiments and viable bacterial counts on agar plates. The
final concentration of enterocin DD28 and enterocin DD93
was 50 mg/l, erythromycin 1 mg/l, kanamycin 4 mg/l and for
combination of bacteriocins with antibiotics the concentrations
used were 50 mg/l for enterocin DD28 and DD93 and 1 mg/l or
4 mg/l, respectively, for erythromycin and kanamycin.
Aliquots were removed at different times 0, 3, 6, 9, and 24 h
of incubation, and then serially diluted in saline solution for
determination of viable counts. Diluted samples (100 µl) were
plated on Tryptone Soya Agar (TSA) plates and colonies were
counted after overnight incubation at 37◦C. Bactericidal activity
was determined as 3 log10 CFU/ml reduction in the colony count
relative to the initial inoculums (Pankuch et al., 1994).
DNA Extraction and PCR Amplification of
Enterocins Codifying DNA
Total DNA from E. faecalis 28 and E. faecalis 93 were
extracted following the same procedure recently described by
Al-Atya et al. (2015). The following forward: ATGGGAGC
AATCGCAAAATTAGTAG and reverse: TTAATGTCTTTT
TAGCCATTTTTCAATTTG primers (Liu et al., 2011) were used
to amplify the genes encoding enterocin L50A and L50B. The
PCR conditions consisted in: initial denaturing step of 5 min
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FIGURE 1 | Mass spectrometry analyses of purified enterocin DD28 (A) and enterocin DD93 (B).
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TABLE 1 | Purification of Enterocins DD 28 and DD93.
Strains Purification
stages
Supernatant
volume
(ml)
Activity
AU/ml
Protein
(mg/ml)
Total
protein
(mg)
Total
activity
Specific
activity
(AU/mg)
Purification
factor
Enterococcus faecalis 28 Supernatant 1 000 800 9.28 9 280 800 000 86.20 1
Sephadex CM
25 50 3 200 0.82 41 160 000 3 902.44 45.27
C18 RP-HPLC 1 6 400 0.095 0.095 6 400 67 368.42 781.53
E. faecalis 93 Supernatant 1 000 800 8.32 8 320 800 000 96.15 1
Sephadex CM
25 50 1 600 0.69 34.5 80 000 2 318.84 24.11
C18 RP-HPLC 1 6 400 0.083 0.083 6 400 77 108.43 801.96
Protein concentration was determined by BiCinchoninic acid Assay (BCA) kit and the manufacturer recommendations (Sigma–Aldrich, USA). Antibacterial activity was
measured against L. innocua CIP80.11 as indictor strain.
TABLE 2 | Antibiotic susceptibility of MRSA-S1 strain.
Antibiotics MIC (mg/l) Antibiotics MIC (mg/l)
Benzylpenicillin R 0.25 Linezolid S 2
Oxacillin R 1 Teicoplanin S ≤ 0.5
Gentamicin S ≤ 0.5 Vancomycin S 1
Kanamycin R 32 Tetracyclin S ≤ 1
Tobramycin R ≥ 16 Fosfomycin S ≤ 8
Ofloxacin S ≤ 0.5 Nitrofurantoin S ≤ 16
Erythromycin R ≥ 8 Fusidic acid S ≤ 0.5
Lincomycin R ≥ 16 Rifampin S ≤ 0.03
Pristinamycin S 1 Trimethoprim-sulfamethoxazole S ≤ 10
R, Resistant; S, Sensitive; MIC, Minimal inhibitory concentration determined by
Vitek 2 system.
TABLE 3 | Determination of minimum inhibitory concentration (MIC).
Strains MIC (mg/l) of
Enterocin DD28
MIC (mg/l) of
Enterocin DD93
Staphylococcus aureus ATCC33862 100 100
Staphylococcus epidermidis 100 100
MRSAATCC 43300 200 200
MRSA-S1 strain 200 200
MRSA-S2 strain 200 200
at 95◦C, followed by 30 cycles of 1 min denaturing at 95◦C,
1 min annealing at a temperature specific for the primers for
each of the known enterocin gene, and 10 min extension at
72◦C. Polymerase chain reaction (PCR) was done using the
PCR Master Mix (2X) (Thermo Scientific Fermentas, Villebon
sur Yvette, France) as a mixture of Taq DNA polymerase. DNA
extraction was performed using the Wizard R© Genomic DNA
Purification Kit (Promega Corp., Madison, WI, USA). Ligation
of PCR products was done into pGEM-T Easy vector (Promega
Corp., Madison, WI, USA). Plasmid extraction was carried out
using GeneJET Plasmid DNA Purification Kit (Thermo Scientific
Fermentas). Restriction endonucleases were supplied by Thermo
Scientific Fermentas. Ligation of inserts to different vectors was
effected using the DNA Ligation Kit < Mighty Mix > from
Takara (Ozyme, Saint Quentin en Yvelines, France). Recovery
of DNA from agarose gels was performed with GeneJET Gel
Extraction kit (Thermo Scientific Fermentas).
In all cases, the instructions of the suppliers were followed.
All the construction sequences were checked by DNA sequencing
performed at Eurofins MWG operon (Ebersberg, Germany).
Biofunctionalization of AISI 304L
Stainless Steel and Glass Slides with
Antimicrobial Compounds
To study the effect of treatment of stainless steel slide,
reproducing abiotic surfaces used in healthcare units and
industries environment, we used the protocol adapted from
Ait Ouali et al. (2014). Briefly 2 ml of antimicrobials at
their MIC values: enterocin DD28 (200 mg/l), enterocin
DD93 (200 mg/l), erythromycin (8 mg/l), ofloxacin (0.5 mg/l),
vancomycin (1 mg/l), rifampin (0.03 mg/l), and combination of
enterocin DD28 with erythromycin (50/1 mg/l) were added on
the surface of each AISI 304L slide placed in sterile Petri plates,
and incubated for 2 h at 37◦C. During this step a conditioning
film on the AISI surface may be formed. Sterile Tryptone Soy
Broth – Yeast Extract (TSB-YE) was added in an additional
AISI304L slide as a control for this conditioning step. After
this step the antimicrobial compounds and the TSB-YE were
removed and replaced by 2 ml of MRSA-S1 strain suspension
at 107 CFU/ml. After 1 h of incubation time, the supernatant
containing non-adherent MRSA-S1 strain cells was removed and
replaced by 2 ml of sterile TSB-YE medium on the surface of
each slide, and the incubation was conducted for 0, 3, 6, and
24 h to survey the installation of MRSA-S1 strain biofilm. After
each time of incubation, the slides were washed twice with 30 ml
of Phosphate Buffered Saline (PBS) (pH 7.0). Finally, the AISI
304L stainless steel slides were immersed individually in 30 ml
phosphate buffer and sonicated. The detached MRSA-S1 cells
were enumerated by plating the bacteria on TSA after growth
at 37 ◦C for 24 h. Additional slides were prepared and served
for epifluorescence observation after their staining with live/dead
components as explained below.
For scanning electron microscope (SEM) analysis, sterilized
glass slides of 1 cm2 were deposited in wells of sterile
24-well tissue culture plates (BD Falcon, USA). Then, as
Frontiers in Microbiology | www.frontiersin.org 5 May 2016 | Volume 7 | Article 817
fmicb-07-00817 May 28, 2016 Time: 15:54 # 6
Al Atya et al. Bacteriocins in Fightings Bacterial Resistance
TABLE 4 | Effects of antimicrobials combinations against MRSA-S1 strain.
Strain DD28 (mg/l) Kanamycin (mg/l) Erythromycin (mg/l) DD28- Kanamycin (mg/l) FIC DD28- Erythromycin (mg/l) FIC
MRSA-S1 200 32 16 50/4 0.375 50/1 0.31
DD93 (mg/l) Kanamycin (mg/l) Erythromycin (mg/l) DD93- Kanamycin (mg/l) FIC DD93- Erythromycin (mg/l) FIC
MRSA-S1 200 32 16 50/4 0.375 50/1 0.31
Fractional Inhibitory Concentration (FIC) index. The data (±SD) are the average of at least three independent experiments. (MIC are given in mg/l). Kanamycin sulfate
(K4000-5G) and Erythromycin (E 5389-5G) were obtained from Sigma–Aldrich (USA).
previously, the glass slides were treated with 2 ml of these
following antimicrobial compounds : enterocin DD28 (200 mg/l),
vancomycin (1 mg/l) and combination of enterocin DD28
with erythromycin (50/1 mg/l), or TSB-YE medium as control,
during 2 h at 37◦C. After this conditioning step of the glass
slides, the antimicrobial compounds solutions were removed and
replaced by 2 ml of MRSA suspension at 107 CFU/ml. The
following steps are exactly the same applied on the AISI304L
FIGURE 2 | Time-killing kinetics on planktonic cultures of MRSA-S1
strain at 0, 3, 6, 9, and 24 h in the presence of enterocins DD28 and
DD93 (50 mg/l) alone or combined with kanamycin (4 mg/l) and
erythromycin (1 mg/l) against SARM-S1. (A) Shows the effect of enterocin
DD28+Kanamycin at 50 mg/l-4 mg/l and enterocin DD28+erythromycin at
50-1 mg/l against MRSA-S1. (B) Shows the effect of enterocin
DD93+kanamycin (50-4 mg/l) and enterocin DD93+erythromycin (50-1 mg/l)
against MRSA-S1. The data (±SD) are the average of at least three
independent experiments. In each experiment, three measures were
performed.
stainless steel slides; however, incubation was conducted for 5
consecutive days, changing the TSB-YE medium each 24 h. Once
the incubation ended, the glass slides were prepared for SEM
analysis.
Epifluorescence and SEM Microscopy
Analyses
Biofilm cells were stained with a BacLight LIVE/DEAD bacterial
viability staining kit according to the manufacturer’s instructions
(Molecular Probes, Invitrogen, France). After dilution of 1.5 µl
of each reagent with 1 ml of physiological water (0.85% m/v
NaCl), the obtained mixture was gently deposited on the upper
face of the slide where the biofilm development may occurred.
Following the incubation (15 min in the dark) of the slides,
the staining solution was aspirated and biofilms were observed
using an epifluorescence microscope (Nikon Optiphot-2 EFD3,
Japan).
RESULTS
Assessment of Enterocins DD28 and
DD93 Amounts upon Purification
Process
The first step of the purification procedure permitted to enhance
the specific activity recovered from the CFS, from 86.20 to
3,902.44 AU/mg (enterocin DD28) and 96.15 to 2,318.84 AU/mg
(enterocin DD93) (Table 1). The second purification step
involving a separation on RP-HPLC column permitted to purify
these enterocins to homogeneity and evaluate their runtime
to 42.5 min. Importantly, the specific activity has increased to
67,368.42 AU/mg for enterocin DD28 and 77,108.43 AU/mg for
enterocin DD93 (Table 1). The purified enterocins DD28 and
DD93 were analyzed by mass spectrometry and appeared to have
very close molecular masses of, respectively, 5,205.21 Da and
5,204.89 Da (Figure 1).
Enterocins DD28 and DD93 were Active
against Staphylococci
Different S. aureus strains were used to demonstrate the
enterocins antibacterial activity. Thus strains S. epidermidis,
S. aureus ATCC 33862, MRSA ATCC 43300, MRSA-S1, and
MRSA-S2 were used as target strains. The MICs values were
similar for S. epidermidis and S. aureus ATCC 33862, but
they were twice higher for MRSA ATCC 43300, MRSA-
S1 and MRSA-S2 strains. For this study, we have then
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FIGURE 3 | Alignment of putative enterocins DD98 and DD93 DNA sequences using ClustalO (http://www.ebi.ac.uk/Tools/msa/) software. (.) Sign
indicates same nucleotide in the considered position for all the sequences aligned.
proceeded with MRSA-S1 strain that was previously isolated
from the blood of an 83 years old patient and studied for its
susceptibility to chromagranin-derived peptides (Aslam et al.,
2013).
Antibiotics Resistance of MRSA-S1
Clinical Strain
The susceptibility of MRSA-S1 strain as determined by VITEK2
method showed resistance to erythromycin and kanamycin with
MICs values of ≥8 mg/l and 32 mg/l, respectively. In turns,
this strain exhibited sensibility to ofloxacin (0.5 mg/l), rifampin
(0.03 mg/l), and vancomycin (1 mg/l) (Table 2). Notably, both
enterocins DD28 and DD93 showed inhibition against MRSA-S1
strain and S. aureus ATCC 33862 used as controls (Table 3).
The MICs values were 100 mg/l for S. aureus ATCC 33862, and
200 µg/ml for MRSA-S1 strain (Table 3).
Checkerboard Assays Revealed a
Synergistic Effect of Enterocins DD28
and DD93 with Antibiotics
When erythromycin and kanamycin were used in combination
with enterocin DD28 or enterocin DD93, the MICs values
were lower than those obtained when these molecules were
tested individually. These combinations permitted a synergetic
effect regarding the FIC values of 0.31 registered for both
enterocins DD28 and DD93, in combination with erythromycin
and kanamycin on MRSA (Table 4). As evidenced from this
assay, the MICs values of erythromycin and kanamycin have
TABLE 5 | Effect of DD28-Kanamycin, DD28-Erythromycin, DD93-Kanamycin, and DD93-Kanamycin combination against MRSA-S1.
Combination 0 h 3 h 6 h 9 h 24 h
Control 5.41 ± 0.08 6.64 ± 0.15 7.52 ± 0.26 8.12 ± 0.12 6.54 ± 0.16
DD28-Kanamycin (50-4 mg/l) 5.52 ± 0.14 2.45 ± 0.26 2.52 ± 0.15 2.47 ± 0.12 2.33 ± 0.20
DD28-Erythromycin (50-1 mg/l) 5.6 ± 0.26 2.58 ± 0.05 2.53 ± 0.07 2.65 ± 0.32 2.49 ± 0.24
DD93-Kanamycin (50-4 mg/l) 5.42 ± 0.03 2.41 ± 0.08 2.43 ± 0.22 2.38 ± 0.05 2.34 ± 0.23
DD93-Erythromycin (50-1 mg/l) 5.55 ± 0.07 2.50 ± 0.2 2.54 ± 0.13 2.40 ± 0.07 2.54 ± 0.22
Log10 colony count lower than that at time Zero without antimicrobial agent (control). −1 = 1 1 Log10 CFU/ml = 90% killing; −2 = 1 2 Log10 CFU/ml = 99% killing;
−3 = 1 3 Log10 CFU/ml = 99.9% killing.
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FIGURE 4 | Biofilms formation by MRSA-S1 strain on AISI 304L stainless steel slides conditioned with antimicrobial agents for 2 h and then washed
and inoculated with 2 ml of 107 CFU/ml MRSA-S1 culture before removing, washing and adding TSB-YE medium for 0, 3, 6, and 24 h of incubation at
37◦C. Concentrations of antimicrobial agents used were 8 mg/l for erythromycin, 0.03 mg/l for rifampin, 200 mg/L for enterocin DD28, 50 mg/l + 1 mg/l for
enterocin DD28 + erythromycin, respectively. Biofilms were stained with the BacLight Live/Dead Viability Kit and imaged by epifluorescence microscopy after
staining pattern for live cells (green) and dead cells (red). The experiments were performed at least twice and representative images are shown.
TABLE 6 | Effect of antimicrobials on MRSA-S1 biofilm formation at different incubation times on AISI 304L stainless steel slides.
Time (h) 0 h 3 h 6 h 24 h
Control 5.55 ± 0.08 7.25 ± 0.15 7.81 ± 0.18 8.85 ± 0.11
Erythromycin (8 mg/l) 5.25 ± 0.25 7.09 ± 0.19 7.39 ± 0.29 8.57 ± 0.12
Ofloxacin (0.5 mg/l) 3.12 ± 0.12 5.24 ± 0.22 5.58 ± 0.18 6.45 ± 0.13
Vancomycin (1 mg/l) 3.10 ± 0.08 5.29 ± 0.19 5.20 ± 0.14 6.10 ± 0.03
Rifampin (0.03 mg/l) 3.11 ± 0.10 5.17 ± 0.11 5.28 ± 0.17 6.06 ± 0.04
Enterocin DD28 (200 mg/l) 3.29 ± 0.10 5.51 ± 0.10 5.62 ± 0.13 6.54 ± 0.12
Enterocin DD93 (200 mg/ml) 3.35 ± 0.21 5.59 ± 0.10 5.58 ± 0.19 6.58 ± 0.17
Erythromycin / DD28 (1/50 mg/l) 3.35 ± 0.10 5.32 ± 0.17 5.15 ± 0.25 6.13 ± 0.10
The data (Log10 CFU/ml) (±SD) are the means of at least three independent experiments.
dropped under their breakpoint points (EUCAST, 2016) when
they were associated to enterocins DD28 and DD93.
Killing Curves Kinetics Confirmed the
Synergistic Effects
The killing curves experiments realized on MRSA-S1
strain treated with erythromycin and kanamycin and their
combinations with enterocins DD28 or DD93 have confirmed
the synergistic effect anticipated by the FIC values. As expected,
the aforementioned antibiotics are devoid of any inhibitory
activity against the planktonic MRSA-S1 culture. The population
number as means of CFU/ml remained identical in the untreated
samples, as well as in those treated with erythromycin and
kanamycin alone portraying this lack of activity. Nevertheless, the
combination of enterocins DD28 and DD93 with erythromycin
and kanamycin reduced the CFU/ml counts of MRSA-S1 by at
least 2–3 logs during 3–24 h of incubation, leading to a killing
of 99–99.9% of the CFU/ml of the initial bacterial populations
(Figure 2; Table 5).
Sequence Alignments and Blast Analysis
Amplification of total DNA from E. faecalis 28 and E. faecalis
93 with the reverse and forward primers previously used to
amplify DNA coding for enterocins L50A and L50B (Cintas et al.,
1998) permitted in the present study to obtain 287 bp DNA
amplicons. Afterward, these amplicons were successfully cloned
into the pGEM-T plasmid and sequenced using 7T and SP6
primers. The resulting sequences were blasted on blastn pubmed
database and showed complete alignment with the sequences
of enterocin MR10A and MR10B (Figure 3), which were two
class IIb bacteriocins produced by E. faecalis MRR 10-3 (Martín-
Platero et al., 2006).
Biofunctionalization of Stainless Steel
and Glass Slides on MRSA Biofilm
Formation
MRSA-S1 exhibited resistance to erythromycin. Thus,
when the AISI 304L stainless steel slides were conditioned
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FIGURE 5 | Scanning electron microscope (SEM) of biofilms formation by MRSA-S1 strain on glass slides. (A) Corresponds to the untreated sample
(control) carrying 5 days old biofilm. (B–D) Show the samples conditionned with enterocin DD28 (200 mg/l), Erythromicin + enterocin DD28 (1–50 mg/l) and
vancomycin (1 mg/l), respectively.
with 8 mg/l erythromycin, biofilm formation, as supported by
epifluorescence microscopy, occurred normally. These results
were comparable to those obtained with the untreated stainless
steel slide (Figure 4; Table 6), advocating that MRSA-S1 biofilm
formation was not affected by this antibiotic. Enterocins DD
28 or DD93 alone, at 200 mg/l, delayed the MRSA-S1 biofilm
formation compared to the control test (Figure 4; Table 6).
Remarkably, this result is similar to those obtained with
vancomycin (1 mg/l) and rifampin (0.03 mg/l), for which the
MRSA-S1 strain exhibited susceptibility (Table 1), and used as
positive controls. Further, the combination of erythromycin and
enterocin DD28 at 1 mg/l and 50 mg/l, respectively, has led to
similar feature as that obtained with antibiotics.
Scanning electron microscope microscopy analysis showed
lower number of adherent MRSA-S1 cells on glass devices after
conditioning with vancomycin (1 mg/l) and a combination of
enterocin DD28+erythromycin (50/1 mg/l), comparatively to
the unconditioned glass slide (Figure 5). However, the biofilm
formation on a glass slide treated with enterocin DD28 alone
(200 mg/l) showed more limited effect on the colonization of the
surface compared to an untreated glass slide (Figure 5).
DISCUSSION
Staphylococcus aureus is the most often species encountered
in the infectious diseases, generally as benign ones, but it
can be involved in more serious infections as pneumonia,
bacterial meningitis, and gastroenteritis. Moreover, this
pathogen was also implied in the nosocomial infections,
sometimes affecting bloodstream, joints, bones, lungs, or
heart, resulting in very complicated infections, even with
fatal epilog (Falcone et al., 2015). The methicillin-resistance
was associated with a resistance to all β-lactams and some
other antibiotics such as aminoglycosides and related macrolides,
synergistines, fluoroquinolones, and fosfomycin. Some molecules
including glycopeptides, rifampin, and fusidic acid remain
active against MRSA (Hamdad et al., 2006; Falcone et al.,
2015).
Staphylococci were shown to form biofilms on abiotic
surfaces such as stainless steel, catheters and polystyrene
material (Otto, 2008), and the biofilm lifestyle stands as a
hurdle to antibiotic treatments that need to be overcome. The
icaADBC genes coding for synthesis of exopolysaccharide of
polymer matrix were shown to be involved in the biofilm
formation (Tremblay et al., 2014). Biofilms act as a physical
barrier, limiting drugs penetration. The ability of biofilm
formation was also observed for other staphylococci species
as S. epidermidis (Tremblay et al., 2014; Agarwal et al.,
2015).
The present study permitted to shed light on the potential of
enterocins DD28 and DD93 to help treating the MRSA burden.
Furthermore, MRSA from hospital settings, are known to be
resistant to erythromycin and kanamycin but remain sensitive to
vancomycin and rifampin (Dumitrescu et al., 2010; Bhattacharya
et al., 2015; Parhizgari et al., 2016).
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Enterocins DD28 and DD93, two class IIb bacteriocins
produced by E. faecalis DD28 and E. faecalis DD93 strains
recently isolated from meconium were purified using the
protocol described by Abriouel et al. (2003) and characterized
for their masses and DNA sequences. Enterocins DD28 and
DD93 masses were perfectly matching with those reported for
enterocins enterocins L50A and L50B (Cintas et al., 2000),
enterocins MR10A and MR10B (Abriouel et al., 2003) and
enterocins A5–11A and A5–11B (Batdorj et al., 2006).
The anti-MRSA activity obtained with the semi-purified
enterocins DD28 and DD93 appeared to be strain dependent.
The highest MIC value was observed for the clinical MRSA-S1
strain, whilst the lowest ones were observed for S. epidermidis
and S. aureus ATCC 33862. The anti-Staphylococcal activities
obtained with enterocins DD28 and DD93 were less pronounced
than the treatment aﬄicted by the antibiotics alone. Nevertheless,
the combinations of these antibiotics with enterocins have
revealed very promising therapeutic options. Indeed, bacteriocins
were able to synergize, as supported by the FICI values and
the killing curves experiments, the effects of antibiotics. The
important drop of MRSA-S1 strain growth, when treated
with enterocin DD28 or DD93 combined to erythromycin or
kanamycin, occurred during the first 3 h of growth. Related
to this, a drop of about 3 Log10 CFU/ml, was registered
upon treatment of MRSA-S1 strain with the aforementioned
antibacterial combinations. Based on this data, we assume that
bacteriocins inputs for the anti-MRSA-S1 activity happened in
the beginning of the treatment before their possible but plausible
degradation. As the anti-MRSA-S1 activity was improved by
the addition of the bacteriocins, and this strain could switch
from a resistant to sensitive phenotype for the tested antibiotics,
we support that anti-MRSA activity could be improved by
incorporation of bacteriocins and the problem of their stability
could be resolved by using encapsulated bacteriocins or
nanoparticles coated bacteriocins.
Staphylococci were also reported to form biofilms on
different biomaterials (Nan et al., 2015) designing them as
guilty of recurrent infections taking place in the healthcare
units (Amalaradjou and Venkitanarayanan, 2014). Mature
biofilms are extremely difficult to eradicate (Dosler and Mataraci,
2013) complicating thereof treatment of this pathogen. The
conditioning of AISI 304L stainless steel and glass slides,
with enterocin DD28 and antibiotics impeded the biofilm
formation by the MRSA-S1 strain. The combinations of
these antimicrobials has not only impacted the growth of
the MRSA-S1 strain under planktonic culture but hampered
the biofilm formation. The MRSA-S1 strain population
was reduced of about 2 Log10 CFU/ml, on AISI 304L
stainless steel slides. This data was logically correlated to
observations resulting from the epifluorescence and SEM
analyses.
CONCLUSION
This study permitted to shed light on the anti-MRSA activity
of enterocins DD28 and DD93. Importantly, these bacteriocins
were able to synergize with erythromycin and kanamycin, two
antibiotics used in the MRSA treatment. The data gathered in the
frame of this work enabled us to confirm the role of bacteriocins
as a novel class of antibiotics to assist or replace the fading
antibiotics. The perfect similarities exhibited by DNA and amino-
acids sequences of enterocins DD28 and DD93 vs. enterocins
MR10A and MR10B let us to think that these bacteriocins are
most probably similar.
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